AKT1 and breast carcinoma: Ock et al. demonstrated that HMH could inactivate the PI3K/AKT/mammalian target of rapamycin (mTOR) signaling pathway in breast cancer cells, and upregulate the expression of FOXO3a, leading to cell cycle arrest in breast cancer (Ock and Kim, 2021).